Investor Connect – Episode 149 – Duke Rohlen of Ajax Health

Investor Connect – Episode 149 – Duke Rohlen of Ajax Health

November 10, 2018 by investor

Duke Rohlen of Ajax Health

In this episode Hall is joined by Duke Rohlen of Ajax Health. The interview starts off with Duke speaking about how he got into medical technology investing for over the last fifteen years. It became a passion between his love for technical innovation, as well as healthcare. Hall and Duke speak about the current trends in the medical device space and where he sees it moving both strategically and with innovation. You’ll also get Duke’s advice on how and what new investors in the medical technology space should look for when investing. Hall and Duke also speak about how to fill the gap in medical technology development.

 

About Ajax Health– AJAX Health accelerates medical innovation through capital and capabilities. Created in partnership with private equity leaders KKR and Aisling Capital, AJAX invests and takes an operating role in innovative medical companies that improve lives and bring speed, simplicity and cost efficiency to health care. AJAX is led by industry veteran Duke Rohlen and his trusted ecosystem of proven industry and operational experts. AJAX’s team has a proven track record of helping companies of all sizes, stages and structures achieve their value-creation goals.

About Duke– Over 15 years of experience as an executive in medical device companies. Currently Duke serves as CEO of Ajax Health Inc. and Chairman and CEO of EPIX Therapeutics, formerly Advanced Cardiac Therapeutics.

Prior to Ajax and EPIX, Duke served as founder and CEO of Spirox, which he sold to Entellus in 2017 for ~$200.0 million. Duke currently serves on the board of Entellus. Prior to Spirox, he founded and served as CEO of CV Ingenuity, which he sold to Covidien in 2013 for ~$300.0 million. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies prior to being named President. Duke helped drive annual sales to ~$200.0 million, helped the Company through an IPO, conceived of and structured a $300.0 million collaboration with Merck Pharmaceuticals, and ultimately led the sale of the company to EV3 (now Medtronic) for $780.0 million in 2008. Prior to working at FoxHollow, Duke held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners. Mr. Rohlen began his professional career as the founder and President of a 9 unit, ~$20.0 million per year restaurant company. Mr. Rohlen received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

 

You can find Ajax Health at https://ent.stryker.com/
Duke can be reached on LinkedIn at https://www.linkedin.com/in/duke-rohlen-7610a2a/>
For more information about Investor Connect or Hall T. Martin, please visit the site at: www.InvestorConnect.org.

____________________________________________________

Copyright (c) 2018, Hall Martin and investorconnect.org. All rights reserved.

NOTE: Investor Connect is a program under the Texas Open Angel Network which is a 501(c3) non-profit dedicated to the education around startup funding. Hall Martin is the principal contact, and he may be reached at http://www.investorconnect.org/contact.

Music: http://www.bensound.com